• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics
  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Sight Sciences Presents Additional Results of OLYMPIA Study Demonstrating Successful Treatment of Signs and Symptoms of Dry Eye Disease Using TearCare

Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium show the novel eyelid procedure successfully achieved clinically meaningful reductions in signs and symptoms of dry eye

Sight Sciences Logo (PRNewsfoto/Sight Sciences, Inc.)

News provided by

Sight Sciences, Inc.

Sep 09, 2020, 09:03 ET

Share this article

Share this article


MENLO PARK, Calif., Sept. 9, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage ophthalmic medical device company, today announced further favorable results of a trial evaluating a single treatment of TearCare® for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for conditions such as meibomian gland dysfunction, dry eye, or blepharitis.

Data from the study were presented at the Women in Ophthalmology (WIO) 2020 Virtual Summer. The Symposium is uniquely curated to offer "the best of the best" content in all subjects important to women ophthalmologists, including dry eye disease, which disproportionately impacts female patients.

The OLYMPIA study was designed to evaluate the safety and effectiveness of a single TearCare procedure compared to a single LipiFlow® procedure (Johnson & Johnson, Jacksonville, Fla.) in treating the signs and symptoms of dry eye disease. OLYMPIA was a prospective, randomized, multicenter trial that enrolled 235 dry eye patients at 10 U.S. sites. All the patients enrolled in the study had moderate to severe stage of dry eye disease associated with meibomian gland dysfunction. Seventy percent of enrolled patients were female.

Results from the OLYMPIA study in the subset of female subjects were presented at the Symposium by Jennifer Loh, M.D., practicing ophthalmologist at Loh Ophthalmology in Miami. In the subset of female subjects, a greater proportion of female TearCare patients experienced meaningful symptomatic relief compared to female LipiFlow patients, as measured by an improvement from baseline in ocular surface disease index (OSDI) score at one month. In the study, 76% of female subjects receiving TearCare improved by at least one OSDI severity category at one month, as compared to 56% of LipiFlow female patients. Similarly, 90% of female subjects receiving TearCare were observed to have clinically meaningful reductions (10.4 point reduction in severe cases and 7.3 point reduction in moderate cases) in OSDI scores from baseline, as compared to 79% of female subjects receiving LipiFlow.

"We are proud to have Dr. Loh present these findings at the WIO Symposium, as we continue to evaluate TearCare for the treatment of dry eye disease," said Paul Badawi, Chief Executive Officer of Sight Sciences. "We believe the OLYMPIA clinical results support the physiologic thesis behind the TearCare procedure for meibomian gland dysfunction, the leading cause of dry eye disease."

The results of the OLYMPIA study show statistically significant and clinically meaningful improvement in the primary signs of dry eye at two weeks that lasted through the duration of the study. Subjects receiving TearCare were observed to have increased tear break-up time (TBUT) by 2.7 ± 3.7 at two weeks and by 3.0 ± 4.2 seconds at one month (both p < 0.0001), and meibomian gland secretion (MGS) score by 10.5 ± 10.9 at two weeks and by 11.2 ± 11.1 units at one month (both p < 0.0001) compared with baseline. Subjects receiving LipiFlow were also observed to have significantly increased TBUT and MGS score at two weeks and one month compared with baseline (all p < 0.0001). The improvements in signs for TearCare patients was numerically better compared to LipiFlow patients.

The results also show statistically significant and clinically meaningful improvement in symptoms measured as patient reported outcomes {OSDI, Symptom Assessment Questionnaire in Dry Eye (SANDE) and Eye Dryness Score (EDS)} at one month. Subjects receiving TearCare reported mean reductions of 27.6 ± 20.6, 38.2 ± 31.0 and 35.4 ± 34.1 respectively in OSDI, SANDE and EDS scores from baseline; all p < 0.0001. Subjects in the LipiFlow group reported mean reductions of 23.4 ± 17.7, 39.4 ± 25.9 and 34.8 ± 26.9 respectively in OSDI, SANDE and EDS scores from baseline; all p < 0.0001. TearCare subjects exhibited better symptomatic relief evidenced by requiring 22% less lubricant drops as a rescue therapy than LipiFlow subjects throughout the study period of one month (p<0.01). Adverse events in OLYMPIA (seven in the TearCare group and eight in the LipiFlow group) were transient, minor and resolved without requiring any further treatment.

Initial results from the OLYMPIA study were presented in May 2020 at the American Society of Cataract Refractive Surgery (ASCRS) Virtual Annual Meeting by Dr. Loh.

About Sight Sciences
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered ophthalmic products. The company's surgical product portfolio features the OMNI® Surgical System, a dually-indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm's canal, and collector channels) with a single device and single corneal incision.

The company's non-surgical product portfolio consists of TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed for the application of localized heat, which may be used to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea.

About TearCare
TearCare is the world's first wearable and intelligent eyelid technology for the application of localized heat to the eyelids. Through a combination of proprietary eyelid innovations including wearability, total tarsal conformance, blink assistance, and software-sensor controlled thermal optimization, TearCare safely, consistently, and non-invasively achieves and maintains the elevated tarsal conjunctival temperatures required to melt gland obstructions, permitting clearance of the critical oil-producing function of the meibomian glands within the eyelid that help to produce a healthy tear film.

TearCare is currently indicated for the application of localized heat when the current medical community recommends the application of a warm compress to the eyelids. Such applications would include Meibomian Gland Dysfunction (MGD), Dry Eye, or Blepharitis.

For more information, please visit sightsciences.com

TearCare® and OMNI® are registered trademarks of Sight Sciences.
© 2020 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
[email protected]

SOURCE Sight Sciences, Inc.

Related Links

http://www.sightsciences.com

Modal title

Also from this source

Sight Sciences Receives FDA Clearance for Expanded Indication for ...

Sight Sciences Receives FDA Clearance for Expanded Indication for ...


Sight Sciences Announces Substantial Crossover Raise...

Sight Sciences Announces Substantial Crossover Raise...

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Medical Equipment
  • Clinical Trials & Medical Discoveries
  • Trade Show News

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.